Inga Wieling

Alere Diagnostics GmbH develops diagnostics to detect circulating tumor cells in tumor patients. The company's tumor diagnostics are kits consisting of reagents for immunomagnetic selection, mRNA isolation and multiplex RT-PCR and can be performed on standard technology platforms. The products have analytical sensitivity (2 cells in 5 ml blood) and specificity (greater 90%) achieved through the combination of multi-marker tumor cell enrichment and multiplex gene expression profiling for treatment of cancer. The company was founded in 1999 and is headquartered in Langenhagen, Germany.

Alere Diagnostics GmbH develops diagnostics to detect circulating tumor cells in tumor patients. The company's tumor diagnostics are kits consisting of reagents for immunomagnetic selection, mRNA isolation and multiplex RT-PCR and can be performed on standard technology platforms. The products have analytical sensitivity (2 cells in 5 ml blood) and specificity (greater 90%) achieved through the combination of multi-marker tumor cell enrichment and multiplex gene expression profiling for treatment of cancer. The company was founded in 1999 and is headquartered in Langenhagen, Germany.

Alere Diagnostics GmbH develops diagnostics to detect circulating tumor cells in tumor patients. The company's tumor diagnostics are kits consisting of reagents for immunomagnetic selection, mRNA isolation and multiplex RT-PCR and can be performed on standard technology platforms. The products have analytical sensitivity (2 cells in 5 ml blood) and specificity (greater 90%) achieved through the combination of multi-marker tumor cell enrichment and multiplex gene expression profiling for treatment of cancer. The company was founded in 1999 and is headquartered in Langenhagen, Germany.

Alere Diagnostics GmbH develops diagnostics to detect circulating tumor cells in tumor patients. The company's tumor diagnostics are kits consisting of reagents for immunomagnetic selection, mRNA isolation and multiplex RT-PCR and can be performed on standard technology platforms. The products have analytical sensitivity (2 cells in 5 ml blood) and specificity (greater 90%) achieved through the combination of multi-marker tumor cell enrichment and multiplex gene expression profiling for treatment of cancer. The company was founded in 1999 and is headquartered in Langenhagen, Germany.

Alere Diagnostics GmbH develops diagnostics to detect circulating tumor cells in tumor patients. The company's tumor diagnostics are kits consisting of reagents for immunomagnetic selection, mRNA isolation and multiplex RT-PCR and can be performed on standard technology platforms. The products have analytical sensitivity (2 cells in 5 ml blood) and specificity (greater 90%) achieved through the combination of multi-marker tumor cell enrichment and multiplex gene expression profiling for treatment of cancer. The company was founded in 1999 and is headquartered in Langenhagen, Germany.